# Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) — Stock CV

Madrigal Pharmaceuticals, Inc. is a $10.9B healthcare company. Revenue grew 149.0% over the last year, it currently loses money, and it holds more cash than debt.

> Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature…

## Identity

- **Ticker**: MDGL
- **Sector**: Healthcare
- **Industry**: Pharmaceutical Preparations
- **Headquarters**: WEST CONSHOHOCKEN, PA
- **Employees**: 915
- **Website**: https://www.madrigalpharma.com
- **Market cap**: $10.9B
- **Last price**: $471.75
- **Financial profile**: Strong

## Vitals (TTM)

- **Revenue**: $1.28B
- **Net income**: -$325M
- **Free cash flow**: -$207M
- **Net cash**: $644M
- **Revenue growth (YoY)**: 149.0%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 22 |
| Growth | 0 |
| Profitability | 0 |
| Health | 75 |
| Quality | 5 |
| Moat | 0 |

## Qualifications (beginner checklist) — 5 of 9 passed

- [x] Revenue growing — +149.0% YoY
- [ ] Profitable — -$325M TTM
- [x] Profit growing — +38.1% YoY
- [ ] Generates cash — -$207M TTM
- [x] Debt under control — more cash than debt
- [x] Established company — $10.9B market cap
- [ ] Not printing shares — +31.2% shares over ~5y
- [ ] Proven track record — 0/10 profitable years
- [x] Financially stable — Altman Z 7.5 — safe

## Strengths

- High gross margin (91.5%)
- Revenue growing 149.0% year over year
- Net cash position after subtracting debt from cash
- Altman Z-Score 7.49 — low bankruptcy-risk zone

## Watch-outs

- Not profitable — 25.3% net margin
- Negative free cash flow (-$207.1M)
- Thin interest coverage (-163.1×)
- Loss-making in 10 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $0 | -$242M | -$184M |
| FY2022 | — | -$295M | -$225M |
| FY2023 | $0 | -$374M | -$326M |
| FY2024 | $180M | -$466M | -$457M |
| FY2025 | $958M | -$288M | -$190M |

---

Source: https://stockcv.com/MDGL — derived from company filings; may be delayed or incomplete. Information, not investment advice.